Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2017. Module: SNOMED CT core
Descriptions:
Id | Description | Lang | Type | Status | Case? | Module |
5183296017 | Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
5183299012 | Cobicistat 150 mg and elvitegravir 150 mg and emtricitabine 200 mg and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
3487410012 | Product containing cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide 10 milligram in oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
3487411011 | Cobicistat 150 mg and elvitegravir 150 mg and emtricitabine 200 mg and tenofovir alafenamide 10 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
3487412016 | Product containing cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide 10 milligram in oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
3571037013 | Product containing only cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide 10 milligram in oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
3571038015 | Product containing only cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide 10 milligram in oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
3677807013 | Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide 10 milligram/1 each conventional release oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
3677808015 | Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide 10 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
5183296017 | Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
5183299012 | Cobicistat 150 mg and elvitegravir 150 mg and emtricitabine 200 mg and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Cobicistat- and elvitegravir- and emtricitabine- and tenofovir-containing product in oral dose form | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | Conventional release oral tablet (dose form) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit (attribute) | mg | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 5 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 5 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 5 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit (attribute) | mg | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 6 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 6 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 6 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit (attribute) | mg | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 7 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 7 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 7 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Cobicistat | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 8 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Cobicistat | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 8 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 150 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 8 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit (attribute) | mg | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 8 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 8 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 8 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Elvitegravir | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 6 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Elvitegravir | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 6 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 150 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 6 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Emtricitabine (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 7 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Emtricitabine (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 7 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 200 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 7 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Tenofovir alafenamide (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 5 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Tenofovir alafenamide (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 5 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | dix | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 5 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit (attribute) | mg | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 4 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 150 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit (attribute) | mg | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit (attribute) | mg | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit (attribute) | mg | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 4 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 150 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 4 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Cobicistat | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Cobicistat | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Emtricitabine (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 200 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Elvitegravir | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Elvitegravir | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Emtricitabine (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | dix | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 4 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Tenofovir alafenamide (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 4 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Tenofovir alafenamide (substance) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 4 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Count of base of active ingredient | quatre | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Cobicistat and elvitegravir and emtricitabine and tenofovir only product in oral dose form | true | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Plays role | Antiretroviral therapeutic role | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Cobicistat | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Emtricitabine (substance) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Emtricitabine (substance) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Cobicistat | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
Product containing precisely cobicistat 150 milligram and elvitegravir 150 milligram and emtricitabine 200 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 10 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Tenofovir alafenamide fumarate (substance) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 4 |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets